Table 1.
Patient characteristics
| Sex (male/female) | 45/39 |
| Median age (range), years | 69 (41–88) |
| Newly diagnosed | 61 (73%) |
| Relapsed/refractory | 23 (27%) |
| Immunoglobulin class | |
| IgG | 49 (58%) |
| IgA | 15 (18%) |
| IgD | 3 (4%) |
| Light chain only | 16 (19%) |
| Non-secretory | 1 (1%) |
| PS (ECOG) | |
| 0 | 29 (35%) |
| 1 | 26 (31%) |
| 2 | 11 (13%) |
| 3 | 11 (13%) |
| 4 | 7 (8%) |
| Durie and Salmon stage | |
| I | 0 (0%) |
| II | 26 (31%) |
| III | 58 (69%) |
| A | 67 (80%) |
| B | 17 (20%) |
| ISS stage | |
| 1 | 26 (31%) |
| 2 | 31 (37%) |
| 3 | 27 (32%) |
| Bone scale | |
| 1 | 14 (17%) |
| 2 | 47 (56%) |
| 3 | 23 (27%) |
| AL amyloidosis | 4 (5%) |
| Anti-myeloma treatment | |
| Proteasome inhibitors | 84 (100%) |
| IMiDs | 59 (70%) |
| ASCT | 26 (31%) |
PS performance status, ECOG Eastern Cooperative Oncology Group, ISS International Staging System, SRE skeletal-related event, IMiD immunomodulatory drug, ASCT autologous stem cell transplantation